COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients

Abstract

Background The COVID-19 pandemic remains a significant global threat. However, despite urgent need, there remains uncertainty surrounding best practices for pharmaceutical interventions to treat COVID-19. In particular, conflicting evidence has emerged surrounding the use of hydroxychloroquine and azithromycin, alone or in combination, for COVID-19. The COVID-19 Evidence Accelerator convened by the Reagan-Udall Foundation for the FDA, in collaboration with Friends of Cancer Research, assembled experts from the health systems research, regulatory science, data science, and epidemiology to participate in a large parallel analysis of different data sets to further explore the effectiveness of these treatments. Methods Electronic health record (EHR) and claims data were extracted from seven separate databases. Parallel analyses were undertaken on data extracted from each source. Each analysis examined time to mortality in hospitalized patients treated with hydroxychloroquine, azithromycin, and the two in combination as compared to patients not treated with either drug. Cox proportional hazards models were used, and propensity score methods were undertaken to adjust for confounding. Frequencies of adverse events in each treatment group were also examined. Results Neither hydroxychloroquine nor azithromycin, alone or in combination, were significantly associated with time to mortality among hospitalized COVID-19 patients. No treatment groups appeared to have an elevated risk of adverse events. Conclusion Administration of hydroxychloroquine, azithromycin, and their combination appeared to have no effect on time to mortality in hospitalized COVID-19 patients. Continued research is needed to clarify best practices surrounding treatment of COVID-19.

Ventilator-Associated Pneumonia in COVID-19 Patients: A Retrospective Cohort Study

“…Additionally, COVID-19 patients presented a higher rate of MDR bacterial colonisation at admission toICU (31% vs. 16%) but they didnot have a higher risk of MDR bacterial acquisition during hospitalisation in ICU. We can speculate that the reason for MDR carriage was the high antibiotic intake observed in France during the COVID-19 pandemic in the early months of 2020, especially for azithromycin [ 24 ]. On the other side, the measures of antimicrobial stewardship actually applied in our ICU service could have limited the risk of in-hospital MDR bacterial acquisition [ 25 , 26 , 27 , 28 ].…”

Efficacy of Chloroquine and Hydroxychloroquine for the Treatment of Hospitalized COVID-19 Patients: A Meta-Analysis

“…Twenty-one studies [ 30 , 31 , 86 , 89 , 90 , 92 , 94 , 97 , 98 , 101 , 102 , 106 , 112 , 114 , 117–119 , 121 , 125 , 126 , 130 ] with 25,343 hospitalized COVID-19 patients assessed the effect of chloroquine and hydroxychloroquine on incidences of mechanical ventilation. The overall pooled OR was 1.26 (95% CI: 0.85–1.87) with significant and severe heterogeneity (I 2 = 87%; p Q <0.01).…”

COVID-19 is associated with higher risk of venous thrombosis, but not arterial thrombosis, compared with influenza: Insights from a large US cohort

“…Analytic partners aligned on a common protocol (the current study’s methodology was adapted from the Sentinel Initiative for the FDA Natural History of Coagulopathy in COVID-19 Study Synopsis and Statistical Analysis Plan [ 12 , 13 ]) and conducted analyses independently; methods and results were shared side-by-side to evaluate differences and similarities. This methodology has been successfully applied to other COVID-19 research questions [ 14 ].…”